Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Sanofi eyes filings for multiple sclerosis therapy tolebrutinib, although two of three phase 3 trials miss their primary endpoints.

Biglaw firm Bryan Cave Leighton Paisner is undergoing its second round of layoffs within a year, following a disappointing 2023 with reduced revenue and following layoffs almost a year ago when 47 ...